Physician profile
Jordan S Weiner
NPI 1134240625
$129,105.18
in general payments reported to CMS, 2019-2025
24 companies · $36K in 2025
The $36K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $6,329 · 2021: $14K · 2022: $31K · 2023: $23K · 2024: $18K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Honoraria: $8,000 · Food and Beverage: $5,307 · Travel and Lodging: $3,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $60,081.25 |
| Honoraria | $8,000.00 |
| Food and Beverage | $5,306.83 |
| Travel and Lodging | $3,048.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $125,224.36 | 2019-2025 | Inspire |
| Optinose US, INC. | $1,317.83 | 2019-2024 | |
| Glaxosmithkline, LLC. | $424.86 | 2019-2025 | Nucala |
| Csl Behring | $391.20 | 2019-2024 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $388.47 | 2019-2024 | Dupixent |
| Genzyme Corporation | $352.16 | 2019-2024 | |
| Aerin Medical INC. | $315.33 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $149.87 | 2019-2021 | |
| Kaleo, INC. | $91.41 | 2021-2022 | |
| Intersect Ent, INC. | $82.31 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.48 | 2020-2021 | |
| Stryker Corporation | $45.45 | 2019-2024 | Xpress Loprofile |
| Smith+Nephew, INC. | $37.92 | 2019-2022 | |
| Lucid Diagnostics INC. | $33.01 | 2023 | |
| Shire North American Group INC | $31.80 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $22.45 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Medtronic, INC. | $21.44 | 2024 | Sinuva |
| Amgen INC. | $18.52 | 2022 | |
| Pharming Healthcare, INC. | $17.52 | 2021 | |
| Acclarent, INC | $16.83 | 2022 | |
| Ambu INC. | $16.58 | 2023 | |
| Merck Sharp & Dohme LLC | $14.04 | 2021 | |
| Aimmune Therapeutics, INC. | $13.54 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.